|
2025 Journal Article Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase RegistryGomez-Figueroa, Enrique, Orozco-Puga, Patricia, Corona-Vazquez, Cynthia Patricia, Moreno-Bernardino, Carlos, Elizabeth De La Mora-landin, Graciela, Jimenez-Ruiz, Amado, Garcia-Estrada, Christian, Zertuche-Ortuno, Lizeth, Saldivar-Davila, Sergio, Rodriguez-Rivas, Roberto, Bazan-Rodriguez, Lisette, Flores-Rivera, Jose, Kalincik, Tomas, Buzzard, Katherine, Khoury, Samia, Duquette, Pierre, Foschi, Matteo, Surcinelli, Andrea, Weinstock-Guttman, Bianca, Gouider, Riadh, Mrabet, Saloua, Lechner-Scott, Jeannette, Butzkueven, Helmut, Alroughani, Raed, Roos, Izanne, Patti, Francesco, Yamout, Bassem, Grand'maison, Francois, Spitaleri, Daniele ... Ruiz-Sandoval, Jose Luis (2025). Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry. Therapeutic Advances in Neurological Disorders, 18 17562864251399595. doi: 10.1177/17562864251399595 |
|
2025 Journal Article Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2024), 10.1007/s40273-024-01417-4)Campbell, Julie A., Henson, Glen J., Ngwa, Valery Fuh, Ahmad, Hasnat, Taylor, Bruce V., van der Mei, Ingrid, Ramanathan, Sudarshini, Hardy, Todd A., Shaw, Cameron, Garber, Justin, Macdonell, Richard, McCombe, Pamela, John, Nevin, Hodgkinson, Suzanne, van der Walt, Anneke, Lechner-Scott, Jeannette, Roos, Izanne, Kalincik, Tomas, Carroll, William M., Fabis-Pedrini, Marzena, Kermode, Allan G., Butzkueven, Helmut and Palmer, Andrew J. (2025). Correction to: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications (PharmacoEconomics, (2024), 10.1007/s40273-024-01417-4). PharmacoEconomics, 43 (2), 241-241. doi: 10.1007/s40273-024-01461-0 |
|
2025 Journal Article Persistent progression independent of relapse activity in multiple sclerosisZhu, Chao, Zhou, Zhen, Kalincik, Tomas, Roos, Izanne, Buzzard, Katherine, Skibina, Olga, Alroughani, Raed, Kuhle, Jens, Girard, Marc, Grammond, Pierre, Lechner-Scott, Jeannette, Gerlach, Oliver, John, Nevin, Mccombe, Pamela, Macdonell, Richard, Van Pesch, Vincent, Laureys, Guy, Prevost, Julie, Horakova, Dana, Kubala Havrdova, Eva, Castillo-Triviño, Tamara, Ramo-Tello, Cristina, Blanco, Yolanda, Meca-Lallana, Jose E, Lugaresi, Alessandra, Tomassini, Valentina, Cartechini, Elisabetta, Amato, Maria Pia, Spitaleri, Daniele ... Butzkueven, Helmut (2025). Persistent progression independent of relapse activity in multiple sclerosis. Brain Communications, 7 (5) fcaf306, 5. doi: 10.1093/braincomms/fcaf306 |
|
2025 Journal Article Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisMüller, Jannis, Sharmin, Sifat, Lorscheider, Johannes, Ozakbas, Serkan, Karabudak, Rana, Horakova, Dana, Weinstock-Guttman, Bianca, Shaygannejad, Vahid, Etemadifar, Masoud, Alroughani, Raed, Patti, Francesco, Eichau, Sara, Prat, Alexandre, Lugaresi, Alessandra, Tomassini, Valentina, Kermode, Allan G., Amato, Maria Pia, Turkoglu, Recai, Altintas, Ayse, Buzzard, Katherine, Soysal, Aysun, Van Der Walt, Anneke, Butzkueven, Helmut, Blanco, Yolanda, Gerlach, Oliver, Khoury, Samia J., Barnett, Michael, John, Nevin, Lechner-Scott, Jeannette ... Granziera, Cristina (2025). Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 82 (6), 614-625. doi: 10.1001/jamaneurol.2025.0495 |
|
2025 Journal Article MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia GravisBuzzard, Katherine A., Van der Walt, Anneke, Butzkueven, Helmut, Zhang, Wen Wen, Barnett-Tapia, Carolina, Cutter, Gary, Heckmann, Jeannine M., Farr, Pamela, Tran, Carolyn, Sartori, Charlotte, Stupar, Dusko, More, Rein, Sim, Linda, Le, Alison, Tang, Qingxiao, Reddel, Stephen W., Blum, Stefan, Lovas, Gabvor, McCombe, Pamela, Chroni, Elisabeth, Cruse, Belinda, Alroughani, Raed, Tzartos, John, Gomex-Figueroa, Enrique, Boz, Cavit, Karelis, Guntis, Kermode, Allan and Crump, Nicholas (2025). MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis. Muscle and Nerve, 72 (3) mus.28450, 424-432. doi: 10.1002/mus.28450 |
|
2025 Journal Article Amyotrophic lateral sclerosis established as a multistep process across phenotypesZiser, Laura, van Eijk, Ruben P. A., Kiernan, Matthew C., McRae, Allan, Henderson, Robert D., Schultz, David, Needham, Merrilee, Mathers, Susan, McCombe, Pam, Talman, Paul and Vucic, Steve (2025). Amyotrophic lateral sclerosis established as a multistep process across phenotypes. European Journal of Neurology, 32 (1) e16532, e16532. doi: 10.1111/ene.16532 |
|
2025 Journal Article Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsRoberts, Jodie I, Sharmin, Sifat, Horakova, Dana, Kubala Havrdova, Eva, Ozakbas, Serkan, Lugaresi, Alessandra, Tomassini, Valentina, Alroughani, Raed, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Turkoglu, Recai, Maimone, Davide, Yamout, Bassem, Khoury, Samia Joseph, Spitaleri, Daniele, Lechner-Scott, Jeannette, Girard, Marc, Duquette, Pierre, Al-Asmi, Abdullah, Ampapa, Radek, Foschi, Matteo, Surcinelli, Andrea, Patti, Francesco, Van Pesch, Vincent, Ramo-Tello, Cristina, Sánchez-Menoyo, José Luis, Altintas, Ayse, Grammond, Pierre ... Smirnova, Sonya (2025). Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years. Journal of Neurology, Neurosurgery and Psychiatry jnnp-2025-336343, jnnp-2025. doi: 10.1136/jnnp-2025-336343 |
|
2025 Journal Article Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay in Two Half-SiblingsYeow, Dennis, Katz, Matthew, Rodgers, Jonathan, Davis, Mark, Robertson, Thomas, Gardner, R. J. McKinlay and McCombe, Pamela A. (2025). Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay in Two Half-Siblings. Annals of Clinical and Translational Neurology acn3.70236. doi: 10.1002/acn3.70236 |
|
2024 Journal Article Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG–positive NMOSDSiriratnam, Pakeeran, Huda, Saif, Van Der Walt, Anneke, Sanfilippo, Paul G., Sharmin, Sifat, Foong, Yi Chao, Yeh, Wei Z., Zhu, Chao, Khoury, Samia J., Csepany, Tunde, Willekens, Barbara, Etemadifar, Masoud, Ozakbas, Serkan, Nytrova, Petra, Altintas, Ayse, Al-Asmi, Abdullah, Ramo-Tello, Cristina M., Laureys, Guy, Patti, Francesco, Horakova, Dana, Foschi, Matteo, Boz, Cavit, McCombe, Pamela A., Turkoglu, Recai, Lechner-Scott, Jeannette, Roos, Izanne, Kalincik, Tomas, Jokubaitis, Vilija G., Butzkueven, Helmut ... for MSBase (2024). Prevalence of progression independent of relapse activity and relapse-associated worsening in patients with AQP4-IgG–positive NMOSD. Neurology, 103 (12) e209940, 1-8. doi: 10.1212/wnl.0000000000209940 |
|
2024 Journal Article Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: an MSBase registry studyKreiter, Daniel, Kalincik, Tomas, Hupperts, Raymond, Patti, Francesco, Spitaleri, Daniele, Foschi, Matteo, Surcinelli, Andrea, Maimone, Davide, Yamout, Bassem, Khoury, Samia J., Lechner-Scott, Jeannette, Ozakbas, Serkan, Gerlach, Oliver, Turkoglu, R., Soysal, A., Boz, C., Al-Asmi, A., Alkhaboori, J., Amato, M. P., Onofrj, M., Lugaresi, A., Besora, S., Sanchez-Menoyo, J. L., Lapointe, E., Grand’Maison, F., Grammond, P., Butzkueven, H., Van der Walt, A., Taylor, B. V. ... Barnett, M. H. (2024). Effectiveness of disease-modifying treatment on spinal cord lesion formation in relapse-onset multiple sclerosis: an MSBase registry study. CNS Drugs, 38 (11), 921-930. doi: 10.1007/s40263-024-01115-x |
|
2024 Conference Publication DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosisMaltby, Vicki E., Xavier, Alexandre, Monif, Mastura, Min, Myintzu, Fabis-Pedrini, Marzena J., Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G., Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Osborne, Meaghan, Butzkueven, Helmut, Barnett, Michael, Lea, Rodney A. and Lechner-Scott, Jeannette (2024). DNA methylation discriminates between responder and non-responder status in a long-term study of cladribine tablet use in multiple sclerosis. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapiesYeh, Wei Z., Van Der Walt, Anneke, Skibina, Olga G., Kalincik, Tomas, Alroughani, Raed, Kermode, Allan G., Fabis-Pedrini, Marzena J., Carroll, William M., Lechner-Scott, Jeannette, Boz, Cavit, Ozakbas, Serkan, Buzzard, Katherine, Habek, Mario, John, Nevin A., Prat, Alexandre, Girard, Marc, Duquette, Pierre, Baghbanian, Seyed Mohammad, Hodgkinson, Suzanne, Van Pesch, Vincent, Laureys, Guy, Willekens, Barbara, Prevost, Julie, Foschi, Matteo, De Gans, Koen, Horakova, Dana, Havrdova, Eva Kubala, Karabudak, Rana, Patti, Francesco ... for the MSBase Study Group (2024). Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies. Neurology Neuroimmunology and Neuroinflammation, 11 (6) e200328, 1-16. doi: 10.1212/nxi.0000000000200328 |
|
2024 Conference Publication The risk of secondary progressive multiple sclerosis is geographically determined but modifiableSharmin, Sifat, Roos, Izanne, Simpson-Yap, Steve, Malpas, Charles, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Kermode, Allan, Butler, Ernest, Barnett, Michael, Hodgkinson, Suzanne, McCombe, Pamela, Taylor, Bruce, Slee, Mark, Macdonell, Richard, Garber, Justin, Shaw, Cameron, Shuey, Neil, Massey, Jennifer, Hardy, Todd, Parratt, John and Kalincik, Tomas (2024). The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Australia: Progress in MS Research Conference (MS), Perth, WA, Australia, 29 November - 1 December 2023. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Assessing the effect of Riluzole on motor unit discharge propertiesShandiz, Ehsan, Fernandes, Gabriel Lima, Henkin, Joao Saldanha, McCombe, Pamela Ann, Trajano, Gabriel Siqueira and Henderson, Robert David (2024). Assessing the effect of Riluzole on motor unit discharge properties. Brain Sciences, 14 (11) 1053, 1053. doi: 10.3390/brainsci14111053 |
|
2024 Journal Article Diagnosing late-onset Tay-Sachs through next generation sequencing and functional enzyme testing: from genes to enzymesTupil, Ajay R., Rivlin, Warwick, Mccombe, Pamela A., Henderson, Robert D., Rodgers, Jonathan and Vadlamudi, Lata (2024). Diagnosing late-onset Tay-Sachs through next generation sequencing and functional enzyme testing: from genes to enzymes. Neurology Genetics, 10 (6) e200205, e200205. doi: 10.1212/nxg.0000000000200205 |
|
2024 Conference Publication Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaborationLaing, N., Kennerson, M., Lamont, P., Vucic, S., Davis, M., Bryson-Richardson, R., Ravenscroft, G., Perez-Siles, G., Ghaoui, R., Narayanan, R., McCombe, P., Deveson, I., Bryen, S., Grosz, B., Johari, M., Rick, A., Folland, C., Scriba, C., Parmar, J. and Ellis, M. (2024). Closing the gap in diagnosis of neuropathies and late-onset neurological disorders - a trans-Australia collaboration. 29th International Congress of the World-Muscle-Society (WMS), Prague, Czech Republic, 8-12 October 2024. London, United Kingdom: Elsevier. doi: 10.1016/j.nmd.2024.07.328 |
|
2024 Journal Article Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre studySiriratnam, Pakeeran, Sanfilippo, Paul, van der Walt, Anneke, Sharmin, Sifat, Foong, Yi Chao, Yeh, Wei Zhen, Zhu, Chao, Khoury, Samia Joseph, Csepany, Tunde, Willekens, Barbara, Etemadifar, Masoud, Ozakbas,, Serkan, Nytrova, Petra, Altintas, Ayse, Al-Asmi, Abdullah, Yamout, Bassem, Laureys, Guy, Patti, Francesco, Simo, Magdolna, Surcinelli, Andrea, Foschi, Matteo, McCombe, Pamela A, Alroughani, Raed, Sánchez-Menoyo, José Luis, Turkoglu, Recai, Soysal, Aysun, Lechner Scott, Jeanette, Kalincik, Tomas, Butzkueven, Helmut ... Monif, Mastura (2024). Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 96 (4) jnnp-2024-334090, 1-9. doi: 10.1136/jnnp-2024-334090 |
|
2024 Conference Publication Real-world Australian experience with Ofatumumab in the MSBase RegistryBarnett, Michael, van der Walt, Anneke, Butzkueven, Helmut, Kalincik, Tomas, Spelman, Tim, Kermode, Allan, Fabis-Pedrini, Marzena, Carroll, William M., Lechner-Scott, Jeannette, John, Nevin, Hodgkinson, Suzanne, McCombe, Pamela, Macdonell, Richard, Slee, Mark, Migocki, Margaret, Martel, Kate and Schmitt, Birte (2024). Real-world Australian experience with Ofatumumab in the MSBase Registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Conference Publication Real-world experience with Cladribine (Mavenclad) in the MSBase registryButzkueven, Helmut, Spelman, Tim, Van der Walt, Anneke, Hodgkinson, Suzanne, Ozakbas, Serkan, Alroughani, Raed, Kalincik, Tomas, Eichau, Sara, Boz, Cavit, Buzzard, Katherine, Habek, Mario, John, Nevin, Kermode, Allan G., Foschi, Matteo, McCombe, Pamela, Gerlach, Oliver, Prevost, Julie, Meca-Lallana, Jose E., Lapointe, Emmanuelle and Jarvinen, Elina (2024). Real-world experience with Cladribine (Mavenclad) in the MSBase registry. 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Copenhagen, Denmark, 18-20 September 2024. London, United Kingdom: Sage Publications. |
|
2024 Journal Article Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosisRoos, Izanne, Sharmin, Sifat, Malpas, Charles, Ozakbas, Serkan, Lechner-Scott, Jeannette, Hodgkinson, Suzanne, Alroughani, Raed, Eichau Madueño, Sara, Boz, Cavit, van der Walt, Anneke, Butzkueven, Helmut, Buzzard, Katherine, Skibina, Olga, Foschi, Matteo, Grand’Maison, Francois, John, Nevin, Grammond, Pierre, Terzi, Murat, Prévost, Julie, Barnett, Michael, Laureys, Guy, Van Hijfte, Liesbeth, Luis Sanchez-Menoyo, Jose, Blanco, Yolanda, Oh, Jiwon, McCombe, Pamela, Ramo Tello, Cristina, Soysal, Aysun, Prat, Alexandre ... Kalincik, Tomas (2024). Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 30 (9), 1163-1175. doi: 10.1177/13524585241267211 |
